TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
PR NewswireMar 27, 2024
TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors Interim results from an ongoing Phase 1a study in healthy male volunteers will be presented at International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress BOSTON and SEONGNAM, South Korea, March 26, 2024 /PRNewswire/ -- TiumBio Co., Ltd. (Kosdaq: 321550), a clin